NCT05177029 is a Phase 1 clinical trial of Lu AG06466 in Healthy Volunteers, sponsored by H. Lundbeck A/S.

Who is sponsoring NCT05177029?

NCT05177029 is sponsored by H. Lundbeck A/S.

What drugs are being tested in NCT05177029?

Interventions in NCT05177029: Lu AG06466, Placebo.

What condition does NCT05177029 study?

NCT05177029 studies Healthy Volunteers.

Is NCT05177029 still recruiting?

NCT05177029 is currently terminated. Last updated 12 July 2022.

Last reviewed 2022-07-12 · How we verify

NCT05177029

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Terminated Phase 1 Last updated 12 July 2022

What this trial tests

Phase 1 trial testing Lu AG06466 in Healthy Volunteers in 24 participants. Terminated before completion.

Timeline

26 November 2021

Primary endpoint
29 December 2021

29 December 2021

Quick facts

Lead sponsor	H. Lundbeck A/S
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	26 November 2021
Primary completion	29 December 2021
Estimated completion	29 December 2021
Sites	1 location across Japan

Drugs / interventions tested

Lu AG06466 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

H. Lundbeck A/S — full company profile →

Who can join

Adults 20 to 45, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.
Maccarrone M, Di Marzo V, Gertsch J, Grether U, et al · · 2023 · cited 128× · PMID 37164640 · DOI 10.1124/pharmrev.122.000600

Verify or expand the search:

Other trials of Lu AG06466

Trials testing the same drug.

NCT05219838 — Binding and Effects of Lu AG06466 in the Brain of Healthy Men · Phase 1 · completed
NCT05081518 — A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy · Phase 1 · terminated
NCT04990219 — A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis · Phase 1 · terminated
NCT04974359 — A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia · Phase 1 · terminated
NCT04713254 — Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other H. Lundbeck A/S trials

Trials by the same sponsor.

NCT07514858 — A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations · Phase 2 · not yet recruiting
NCT07513441 — A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD) · Phase 1 · not yet recruiting
NCT06701526 — A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications · Phase 4 · active not recruiting
NCT06706622 — A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) · Phase 3 · active not recruiting
NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05177029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lundbeck A/S
Last refreshed: 12 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05177029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing